Salloway S, Gamez JE, Singh U, et al. Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer’s disease. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2017;9:25–34. https://doi.org/10.1016/j.dadm.2017.06.001.

Article  Google Scholar 

Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer’s disease: Phase 3 study. Alzheimer’s Dement. 2015;11:964–74. https://doi.org/10.1016/j.jalz.2015.02.004.

Article  Google Scholar 

Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study. Lancet Neurol. 2012;11:669–78. https://doi.org/10.1016/S1474-4422(12)70142-4.

Article  CAS  PubMed  Google Scholar 

Buckley CJ, Sherwin PF, Smith APL, et al. Validation of an electronic image reader training programme for interpretation of [18F]flutemetamol β-amyloid PET brain images. Nucl Med Commun. 2017;38:234–41. https://doi.org/10.1097/MNM.0000000000000633.

Article  CAS  PubMed  Google Scholar 

De Wilde A, Van Der Flier WM, Pelkmans W, et al. Association of amyloid positron emission tomography with changes in diagnosis and patient treatment in an unselected memory clinic cohort: the ABIDE project. JAMA Neurol. 2018;75:1062–70. https://doi.org/10.1001/jamaneurol.2018.1346.

Article  PubMed  PubMed Central  Google Scholar 

Rabinovici GD, Gatsonis C, Apgar C, et al. Association of amyloid positron emission tomography with subsequent change in clinical management among medicare beneficiaries with mild cognitive impairment or dementia. J Am Med Assoc: JAMA. 2019;321:1286–94. https://doi.org/10.1001/jama.2019.2000.

Article  Google Scholar 

Chiotis K, Saint-Aubert L, Boccardi M, et al. Clinical validity of increased cortical uptake of amyloid ligands on PET as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework. Neurobiol Aging. 2017;52:214–27. https://doi.org/10.1016/j.neurobiolaging.2016.07.012.

Article  CAS  PubMed  Google Scholar 

Fantoni ER, Chalkidou A, O’Brien JT, et al. A systematic review and aggregated analysis on the impact of amyloid PET Brain imaging on the diagnosis, diagnostic confidence, and management of patients being evaluated for Alzheimer’s disease. J Alzheimer’s Dis. 2018;63:783–96. https://doi.org/10.3233/JAD-171093.

Article  Google Scholar 

Barthel H, Sabri O. Clinical use and utility of amyloid imaging. J Nucl Med. 2017;58:1711–7. https://doi.org/10.2967/jnumed.116.185017.

Article  PubMed  Google Scholar 

Grundman M, Johnson KA, Lu M, et al. Effect of amyloid imaging on the diagnosis and management of patients with cognitive decline: impact of appropriate use criteria. Dement Geriatr Cogn Disord. 2016;41:80–92. https://doi.org/10.1159/000441139.

Article  CAS  PubMed  Google Scholar 

Collij LE, Salvadó G, Shekari M, et al. Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. Eur J Nucl Med Mol Imaging. 2021;48:2169–82. https://doi.org/10.1007/s00259-020-05174-2.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Zwan MD, Bouwman FH, Konijnenberg E, et al. Diagnostic impact of [18F]flutemetamol PET in early-onset dementia. Alzheimer’s Res Ther. 2017. https://doi.org/10.1186/s13195-016-0228-4.

Article  Google Scholar 

Pontecorvo MJ, Siderowf A, Dubois B, et al. Effectiveness of florbetapir PET imaging in changing patient management. Dement Geriatr Cogn Disord. 2017;44:129–43. https://doi.org/10.1159/000478007.

Article  PubMed  Google Scholar 

Schipke CG, Peters O, Heuser I, et al. Impact of beta-amyloid-specific florbetaben pet imaging on confidence in early diagnosis of Alzheimer’s disease. Dement Geriatr Cogn Disord. 2012;33:416–22. https://doi.org/10.1159/000339367.

Article  CAS  PubMed  Google Scholar 

Zannas AS, Doraiswamy PM, Shpanskaya KS, et al. Impact of 18F-florbetapir PET imaging of β-amyloid neuritic plaque density on clinical decision-making. Neurocase. 2014;20:466–73. https://doi.org/10.1080/13554794.2013.791867.

Article  PubMed  Google Scholar 

Leuzy A, Savitcheva I, Chiotis K, et al. Clinical impact of [18F]flutemetamol PET among memory clinic patients with an unclear diagnosis. Eur J Nucl Med Mol Imaging. 2019. https://doi.org/10.1007/s00259-019-04297-5.

Article  PubMed  PubMed Central  Google Scholar 

Van Der Flier WM, Scheltens P. Amsterdam dementia cohort: performing research to optimize care. J Alzheimer’s Dis. 2018;62:1091–111. https://doi.org/10.3233/JAD-170850.

Article  Google Scholar 

Fantoni E, Collij L, Alves IL, et al. The spatial-temporal ordering of amyloid pathology and opportunities for PET imaging. J Nucl Med. 2020;61:166–71. https://doi.org/10.2967/jnumed.119.235879.

Article  CAS  PubMed  Google Scholar 

Pontecorvo MJ, Arora AK, Devine M, et al. Quantitation of PET signal as an adjunct to visual interpretation of florbetapir imaging. Eur J Nucl Med Mol Imaging. 2017;44:825–37. https://doi.org/10.1007/s00259-016-3601-4.

Article  PubMed  Google Scholar 

Joshi AD, Pontecorvo MJ, Clark CM, et al. Performance characteristics of amyloid PET with florbetapir F 18 in patients with Alzheimer’s disease and cognitively normal subjects. J Nucl Med. 2012;53:378–84. https://doi.org/10.2967/jnumed.111.090340.

Article  CAS  PubMed  Google Scholar 

Bucci M, Savitcheva I, Farrar G, et al. A multisite analysis of the concordance between visual image interpretation and quantitative analysis of [18F]flutemetamol amyloid PET images. Eur J Nucl Med Mol Imaging. 2021;48:2183–99. https://doi.org/10.1007/s00259-021-05311-5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paghera B, Altomare D, Peli A, et al. Comparison of visual criteria for amyloid-pet reading: could criteria merging reduce inter-rater variability? Q J Nucl Med Mol Imaging. 2021;64:414–21. https://doi.org/10.23736/S1824-4785.19.03124-8.

Article  Google Scholar 

Yamane T, Ishii K, Sakata M, et al. Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging. 2017;44:850–7. https://doi.org/10.1007/s00259-016-3591-2.

Article  CAS  PubMed  Google Scholar 

Lopresti BJ, Klunk WE, Mathis CA, et al. Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med. 2005;46:1959–72.

CAS  PubMed  Google Scholar 

Aisen PS, Cummings J, Doody R, et al. The future of anti-amyloid trials. J Prev Alzheimer’s Dis. 2020;7:146–51. https://doi.org/10.14283/jpad.2020.24.

Article  CAS  Google Scholar 

Blennow K, Zetterberg H. Amyloid and Tau biomarkers in CSF. J Prev Alzheimer’s Dis. 2015;2:1–5. https://doi.org/10.14283/jpad.2015.41.

Article  Google Scholar 

Milà-Alomà M, Salvadó G, Shekari M, et al. Comparative analysis of different definitions of amyloid-β positivity to detect early downstream pathophysiological alterations in preclinical Alzheimer. J Prev Alzheimer’s Dis. 2021;8:68–77. https://doi.org/10.14283/jpad.2020.51.

Article  Google Scholar 

Farrell ME, Jiang S, Schultz AP, et al. Defining the lowest threshold for amyloid-PET to predict future cognitive decline and amyloid accumulation. Neurology. 2021;96:e619–31. https://doi.org/10.1212/WNL.0000000000011214.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Farrell ME, Chen X, Rundle MM, et al. Regional amyloid accumulation and cognitive decline in initially amyloid-negative adults. Neurology. 2018;91:E1809–21. https://doi.org/10.1212/WNL.0000000000006469.

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Kall LM, Truong T, Burnham SC, et al. Association of β-amyloid level, clinical progression, and longitudinal cognitive change in normal older individuals. Neurology. 2021;96:e662–70. https://doi.org/10.1212/WNL.0000000000011222.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hanseeuw BJ, Malotaux V, Dricot L, et al. Defining a centiloid scale threshold predicting long-term progression to dementia in patients attending the memory clinic: an [18F] flutemetamol amyloid PET study. Eur J Nucl Med Mol Imaging. 2021;48:302–10. https://doi.org/10.1007/s00259-020-04942-4.

Article  CAS  PubMed  Google Scholar 

Camus V, Payoux P, Barré L, et al. Using PET with 18F-AV-45 (florbetapir) to quantify brain amyloid load in a clinical environment. Eur J Nucl Med Mol Imaging. 2012;39:621–31. https://doi.org/10.1007/s00259-011-2021-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guerra UP, Nobili FM, Padovani A, et al. Recommendations from the Italian Interdisciplinary Working Group (AIMN, AIP, SINDEM) for the utilization of amyloid imaging in clinical practice. Neurol Sci. 2015;36:1075–81. https://doi.org/10.1007/s10072-015-2079-3.

Article  PubMed  Google Scholar 

Kobylecki C, Langheinrich T, Hinz R, et al. 18F-florbetapir PET in patients with frontotemporal dementia and Alzheimer disease. J Nucl Med. 2015;56:386–91. https://doi.org/10.2967/jnumed.114.147454.

Article  CAS  PubMed  Google Scholar 

Daniela P, Orazio S, Alessandro P, et al. A survey of FDG- and amyloid-PET imaging in dementia and grade analysis. Biomed Res Int. 2014. https://doi.org/10.1155/2014/785039.

Article  PubMed Central  Google Scholar 

Klunk WE, Koeppe RA, Price JC, et al. The Centiloid project: standardizing quantitative amyloid plaque estimation by PET. Alzheimer’s Dement. 2015;11:1-15.e4. https://doi.org/10.1016/j.jalz.2014.07.003.

Article  Google Scholar 

Akamatsu G, Ikari Y, Ohnishi A, et al. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study. EJNMMI Res. 2019. https://doi.org/10.1186/s13550-019-0561-2.

Article  PubMed  PubMed Central